There are influenza epidemics every year. In recent years, diagnosis is rapidly confirmed in a clinic when the virus is detected by diagnosing kits, such as enzyme immunosorbent assays or direct immunofluorescence. In contrast, in a reference laboratory participating in influenza surveillance, the detailed antigenic characterization of isolates is required. In Japan, virus is isolated mainly in Madin-Darby canine kidney (MDCK) cells. Subsequently, it is subtyped by the hemagglutination inhibition (HI) test using the polyclonal ferret sera against influenza virus A or B. To subtype influenza A virus, the antibody has to be prepared continually, because the antigenic drift of hemagglutinin (HA) protein hampers its identification (2, 3, 6) . On the other hand, the evolution of influenza B virus is characterized by a lower rate of antigenic change (7, 8) . Recent isolates of influenza B virus are classified into two major phylogenetic trees: the influenza virus B/Victoria/2/87 subclass or the influenza virus B/Yamagata/16/88 subclass (4, 7, 8, 13, 15, 17) . Group-specific antigens have been conserved among influenza virus B/Yamagata strains. In Japan, the standard ferret sera were prepared using influenza virus B/Mie/1/93 strain for the epidemic seasons in 1994 to 1995 through 1998 to 1999. It reacted well with all the 1998 to 1999 influenza virus B/Yamagata isolates in Osaka Prefecture by HI tests. However, their reactivities against monoclonal antibody (MAb) 5H4 were heterogeneous. MAb 5H4 had potent HI and neutralization activities against the influenza virus B/Yamagata strains isolated earlier. Approximately 6% of the isolates did not react against MAb 5H4, and a single amino acid substitution of Arg to Lys at position 149 in the HA1 region caused the phenomenon (12) .
We studied the variation in antigenicity and nucleotide sequence of the 2000 to 2001 isolates of Kobe City, Japan.
MAbs were obtained by immunizing mice with influenza B virus strains as described previously (9) (10) (11) (12) . Ascitic fluid samples from mice injected with hybridoma cells were used as the sources of MAbs. The standard ferret sera were provided by the National Institute of Health, Tokyo, Japan: the sera against influenza virus B/Yamanashi/166/98 for influenza virus B/Yamagata and the sera against influenza virus B/Shangdong/ 7/97 for influenza virus B/Victoria. The methods for virus inoculation and visualization of infected cells by peroxidaseantiperoxidase (PAP) staining were described previously (9, 14, 16) . Briefly, infected cells were treated successively with MAbs, rabbit anti-mouse immunoglobulin antibody, goat antirabbit immunoglobulin antibody, and PAP complex. The visualized cells were then observed under a light microscope. The results of HI tests are expressed as the reciprocal of antibody dilution (14) . Direct sequencing of viral nucleotide was performed as described previously (10) (11) (12) . Briefly, reverse transcriptase PCR products were sequenced with the DYEnamic ET terminator cycle sequencing kit (Amersham Pharmacia, Piscataway, N.J.) and analyzed by the ABI Prism 310 automatic sequencer (Perkin-Elmer, Foster City, Calif.).
The reactivities of the 2000 to 2001 isolates against antiinfluenza virus B/Yamagata sera in HI tests were as low as 20 to 40, while the reactivities of the earlier influenza virus B/Yamagata isolates ranged from 160 to 320 (Table 1) . The isolates were PAP stained and identified as influenza virus B/Yamagata group strains with MAbs, NP-specific 9F3 and HA-specific 7H11. An influenza virus B/Victoria group HAspecific MAb, MAb10B8, did not react with these isolates. Nucleotide sequences and deduced amino acid sequences of the HA gene indicated that strains with two different origins were isolated in the 2000 to 2001 influenza season (Fig. 1) , as observed in the previous two seasons (12) . Four strains had 99% similarity to influenza virus B/Kadoma/409/2000, which was derived from influenza virus B/Shiga/T30/98, while influenza virus B/Kobe/87/2001 had 98% similarity to influenza virus B/Osaka/1201/2000, which was derived from influenza virus B/Tokyo/942/96. In both groups, there was an Asn-to-Asp substitution at position 126.
Influenza virus B/Kobe/69/2001 had high similarity to influenza virus B/Kadoma/409/2000; however, two nucleotide residues were not determined in direct sequencing, suggesting that the virus was a mixture of more than one strain. Therefore, the virus was cloned, and 21 clones were obtained. When the ferret sera were used in HI tests, 8 clones had HI titers as low as 20, while the remaining 13 clones had titers of 160. HA1 regions of four representative strains were sequenced ( Table 2) . Among 1,060 nucleic acids in the HA1 region, only two points were different, which correspond to two amino acid substitutions. The strains with low reactivities had Phe at position 58 and Asp at position 126, while those with high reactivities had Leu and Asn at these two sites, respectively. Therefore, amino acid substitutions at position 126 strongly influenced the virus reactivity to the ferret sera. Amino acids in HA1 polypeptides of the influenza B virus strains were numbered according to the numbering used for the influenza virus A/Aichi sequence for the structural reference of the H3 HA protein of influenza A virus (1, 5) . The amino acid at position 126 corresponds to the amino acid at position 129 of AH3 virus by this method. Position 126 is located near the receptor region.
The amino acid residues Asn at position 126 and Arg at position 149 had been conserved in influenza virus B/Yamagata group strains for 10 years bodies. This finding is compatible with the idea that the new antigenic variants are generated to escape from the existing human immunity and displace the old variants (6, 7, 11) . Henceforth, influenza virus B/Yamagata group viruses might emerge from the antigenic variants of the influenza virus B/Victoria group (11) and new group strains may appear from the variants of influenza virus B/Yamagata strains. This information will benefit the management of public health (foretelling the scale of future epidemics and selecting suitable strains for vaccines). 
